Itonic Holdings Ltd. (NASDAQ:ITOC) Short Interest Update

Itonic Holdings Ltd. (NASDAQ:ITOC) was the target of a significant drop in short interest in June. As of June 15th, there was short interest totaling 81,183 shares, a drop of 59.0% from the May 31st total of 197,966 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 3,686,350 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Itonic from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 5th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Itonic Stock Performance

NASDAQ:ITOC traded down $0.00 during mid-day trading on Tuesday, hitting $0.30. The company’s stock had a trading volume of 34,973 shares, compared to its average volume of 2,718,449. The business’s fifty day moving average price is $0.33. Itonic has a 1 year low of $0.25 and a 1 year high of $32.00.

Itonic (NASDAQ:ITOC) last issued its earnings results on Monday, March 30th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $0.23 million during the quarter.

About Itonic

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.